NCT03061227

Characterization of Metabolic and Brain Effects of Rising Glucagon During an Oral Glucose Challenge

Metabolic and Central Nervous System Characterisation of the Phenotype of Non-suppressed (Rising) Glucagon After Glucose Challenge

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 32 (actual)
• Sponsor: University Hospital Tuebingen · Academic / Other
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Accepted

Summary

The investigators previously characterized a phenotype with non-suppressed glucagon at 120 minutes after standardized oral glucose load. This phenotype is associated with healthy metabolic traits such as lower BMI, higher insulin sensitivity and lower liver fat content. Glucagon is a pleiotropic hormone that, besides its main action on increasing endogenous glucose production, also reduces appetite and increases basal energy expenditure. The aims of this study are to i. detect functional differences in the appetite-related central nervous system (CNS) areas between the suppressed and non-suppressed glucagon phenotype ii. mimick the non-suppressed glucagon phenotype in those participants who suppress glucagon by administering a very-low-dose glucagon infusion and retest them.

Conditions

• Metabolic Syndrome
• Diabetes

Interventions

Type	Name	Description
DRUG	Intravenous glucagon	Randomized application of glucagon or saline during oral glucose tolerance test
DRUG	Intravenous saline	Randomized application of glucagon or saline during oral glucose tolerance test

Timeline

• Start date: 2017-02-10
• Primary completion: 2019-01-17
• Completion: 2020-04-30
• First posted: 2017-02-23
• Last updated: 2020-05-05

Locations

1 site across 1 country: Germany